<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g133" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-130.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
                <a href="#nav-panel" class="ui-btn ui-icon-bars ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-47.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-87.html" >Diseases Characterized by Genital, Anal, or Perianal Ulcers</a><span class="carrot"> > </span>
                    <a href="lv-87.html" >Syphilis</a><span class="carrot"> > </span>
                    <a href="lv-127.html" >Syphilis Among HIV-Infected Persons</a><span class="carrot"> > </span>
                    <a href="lv-130.html" >Primary and Secondary Syphilis Among HIV- Infected Persons</a><span class="carrot"> > </span>Follow-Up
            </div>
            </br><h5 class="sgc-1 sgc-1" id="sigil_toc_id_133">
 Follow-Up
</h5>
<p>
 HIV-infected persons should be evaluated clinically and serologically for treatment failure at 3, 6, 9, 12, and 24 months after therapy.
</p>
<p>
 HIV-infected persons who meet the criteria for treatment failure (i.e., signs or symptoms that persist or recur or persons who have a sustained fourfold increase in nontreponemal test titer) should be managed in the same manner as HIV-negative patients (i.e., a CSF examination and retreatment). CSF examination and retreatment also should be strongly considered for persons whose nontreponemal test titers do not decrease fourfold within 6&ndash;12 months of therapy. If CSF examination is normal, treatment with benzathine penicillin G administered as 2.4 million units IM each at weekly intervals for 3 weeks is recommended.
</p>

            </div>
        <div data-role="panel" data-display="push" data-theme="b" id="nav-panel">
            <ul data-role="listview">
                <li data-icon="delete"><a href="#" data-rel="close">Close menu</a></li>
                <li><a href="../conditions/c0-clv.html">Condition Quick Pick</a></li>
                <li><a href="../guidelines/lv-0.html">Full STD Tx Guidelines</a></li>
                <li><a href="../page/hx-pdf.html">Taking a Sexual Hx PDF</a></li>
                <li><a href="../terms/1.html">Terms and Abbreviations</a></li>
                <li><a href="../refs/lv-0.html">References</a></li>
                <li><a href="../page/about_us.html">About Us</a></li>
            </ul>
        </div><!-- /panel -->
    
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>
    